Latest progress in tyrosine kinase inhibitors
Metrics: PDF 1138 views | HTML 1486 views | ?
Tatiana V. Pospelova1,2 and Valery A. Pospelov1,2
1 Institute of Cytology, Russian Academy of Sciences, St. Petersburg, Russia
2 Saint Petersburg State University, St. Petersburg, Russia
Tatiana V. Pospelova, email:
Keywords: cancer, mTOR, kinases, c-Met, Bcr-Abl, senescence
Received: March 10, 2014 Accepted: March 20, 2014 Published: March 20, 2014
Here we discuss the latest progress in development of some kinase inhibitors such as inhibitors of c-MET, LIM and Bcr-Abl kinases. Importantly, many oncogenic kinases signal via the mTOR pathway, suggesting a common target for drug combinations.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.